Item 2.02 Results of Operations and Financial Condition.
Repare Therapeutics Inc. (the "Company") intends to share with investors the
amount of cash, cash equivalents, restricted cash and marketable securities it
had on hand as of December 31, 2021. Although the Company has not finalized its
financial results for the twelve months ended December 31, 2021, the Company
preliminarily estimates that its cash, cash equivalents, restricted cash and
marketable securities as of December 31, 2021 was approximately $341.7 million.
The information in this Item 2.02 is unaudited and preliminary, and does not
present all information necessary for an understanding of the Company's
financial condition as of December 31, 2021 and its results of operations for
the three months and year ended December 31, 2021. The audit of the Company's
financial statements for the year ended December 31, 2021 is ongoing. The
Company's actual consolidated cash, cash equivalents, restricted cash and
marketable securities as of December 31, 2021 may differ from these estimates
due to the completion of the Company's year-end closing and auditing procedures.
The information in this Item 2.02 shall not be deemed to be "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall such
information be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses